Table 1 Comparison of baseline data among three groups
Group | p-value | ||||||
|---|---|---|---|---|---|---|---|
Control group (N = 212) | ETV group (N = 220) | TDF group (N = 228) | Chi-Square Tests | Oneway ANOVA | |||
Gender | Female | Count(%) | 67(31.6%) | 64(29.1%) | 75(32.9%) | 0.880 | |
Male | Count(%) | 145(68.4%) | 156(70.9%) | 153(67.1%) | |||
Child-Pugh classification of liver function | A | Count(%) | 140(66.0%) | 139(63.2%) | 135(59.2%) | 0.781 | |
B | Count(%) | 72(34.0%) | 81(36.8%) | 93(40.8%) | |||
BCLC staging | A | Count(%) | 25(11.8%) | 27(12.3%) | 20(8.8%) | 0.896 | |
B | Count(%) | 120(56.6%) | 112(50.9%) | 133(58.3%) | |||
C | Count(%) | 67(31.6%) | 81(36.8%) | 75(32.9%) | |||
ECOG score | 0 | Count(%) | 148(69.8%) | 145(65.9%) | 154(67.5%) | 0.755 | |
1 | Count(%) | 41(19.4%) | 47(21.4%) | 43(18.9%) | |||
2 | Count(%) | 23(10.8%) | 28(12.7%) | 31(13.6%) | |||
Levels of HBV-DNA (IU/ml) | > 2000 | Count(%) | 100(47.2%) | 133(60.5%) | 123(53.9%) | 0.081 | |
100–2000 | Count(%) | 74(34.9%) | 61(27.7%) | 74(32.5%) | |||
< 100 | Count(%) | 38(17.9%) | 26(11.8%) | 31(13.6%) | |||
Age(Years) | Mean ± SD | 47.8 ± 12.1 | 51.3 ± 15.4 | 56.1 ± 18.7 | 0.433 | ||
ALT before treatment(U/L) | Mean ± SD | 51.4 ± 26.3 | 55.6 ± 21.5 | 59.2 ± 20.7 | 0.210 | ||
AST before treatment(U/L) | Mean ± SD | 62.3 ± 20.6 | 57.6 ± 17.1 | 61.5 ± 22.4 | 0.327 | ||
Bilirubin before treatment(µmol/L) | Mean ± SD | 19.6 ± 11.3 | 21.4 ± 13.9 | 20.7 ± 8.5 | 0.155 | ||
HBV-DNA(lgX IU/ml) | Mean ± SD | 4.86 ± 1.75 | 4.53 ± 2.36 | 4.69 ± 2.08 | 0.408 | ||
Albumin(g/L) | Mean ± SD | 32.62 ± 4.60 | 33.18 ± 3.91 | 32.15 ± 4.27 | 0.371 | ||
BUN(mmol/L) | Mean ± SD | 5.79 ± 2.21 | 6.12 ± 1.93 | 5.96 ± 2.16 | 0.256 | ||
Cr(µmol/L) | Mean ± SD | 82.11 ± 25.34 | 79.56 ± 23.71 | 75.44 ± 27.23 | 0.568 | ||
GFR(ml/min) | Mean ± SD | 98.76 ± 19.75 | 104.49 ± 21.02 | 101.52 ± 25.63 | 0.309 | ||